05:03 PM EDT, 05/09/2024 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) reported Q1 net loss Thursday of $0.93 per diluted share, widening from the loss of $0.85 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.80.

Revenue in the three months ended March 31 fell to $640,000 from $2.68 million a year earlier.

The company said its unrestricted cash, cash equivalents and investments were $901 million as of March 31, sufficient to fund the current operating plan into 2028.

Price: 48.60, Change: -0.82, Percent Change: -1.66